BOCA RATON, Fla., May 22, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.
) (Nasdaq: ENTO) (“Entero” or the“Company”), a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it will present at the 2024 BIO International Convention which will be held June 3-6, 2024, in San Diego, California. To schedule a meeting at the BIO International Convention with Entero, please submit a meeting request through the BIO One-on-One PartneringTM platform. For more information about Entero Therapeutics, visit and connect on X and LinkedIn .
About Entero Therapeutics Entero Therapeutics, Inc. (formerly First Wave BioPharma) is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company's programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
For more information visit . Forward-Looking Statements This press release may contain cert.